



\$3.3M AUSTRALIAN GOVERNMENT GRANT TO CO-FUND TETRATHERIX' (ASX:TTX) STRATEGIC PROGRAM

Highlights:

- Tetratherix (ASX:TTX) has been successful in securing a **\$3.3 million non-dilutive** Australian Government Industry Growth Program grant.
- The project, titled '**Synthetic polymer Production Facility to Take Tetramatrix Global**', funds a number of strategic pillars of the company's growth including an expansion of production capacity and key development activities.
- The **\$7.4m** cost of the project is budgeted and aligned with the use of funds in Tetratherix' IPO Prospectus. The project now is co-funded with \$3.3 million support from the Australian Government (\$2.1 million in FY26 and \$1.2 million in FY27).
- Tetratherix will provide quarterly reports that will be assessed against agreed project milestones.
- The grant is provided by the **Australian Government' s Industry Growth Program** and was executed on 13th August 2025.

Tetratherix Limited ("Tetratherix" or "the Company"), a developer of novel clinical products based on its patented biomaterial polymer platform technology, is pleased to announce that it has been awarded an Industry Growth Program grant from the Australian Government.

The Industry Growth Program is for innovative businesses with high growth potential who want to transform and significantly scale up their business and help build Australian manufacturing capability for the future. Tetratherix stands as a clear fit for this mandate: an innovative, science-driven company with global ambitions, built on a foundation of novel biomaterials designed to scale impact across markets.

The expected project cost is **\$7,383,897 from which \$3,322,754** is the grant amount and the remaining **\$4,061,143** is the Company's co-contribution, which is already budgeted and committed as a part of Tetratherix's use of fund in IPO Prospectus. The Industry Growth Program grant funding period is from July 2025 till May 2027.

This grant marks more than just financial support — it is recognition that Tetratherix now sits at the helm of a growing national ecosystem. With its integrated approach to advanced manufacturing and clinician-led development, Tetratherix is helping to reposition Australia as an active builder of commercial medical technologies. From polymer synthesis to clinical trials, the Company is designing and executing the full translational arc in Australia.

One key initiative of the Industry Growth Program funding will directly support the US launch of Tetratherix' bone regeneration franchise in 2026 — a critical step in bringing Australian-made regenerative therapies to one of the world's most advanced healthcare markets. This support ensures the Company is not only ready to meet the regulatory and logistical demands of expansion, but that it can do so while staying true to its vision: pioneering materials, backed by real clinical utility, built in Australia, scaled globally.

For more information on the Industry Growth Program, see: www.business.gov.au/IGP

ASX RELEASE

14 AUGUST 2025



< ENDS >

Authorised for release by CEO and CTO

For further information contact:

Matthew Wright

NWR Communications

+61 (0) 451 896 420

matt@nwrcommunications.com.au

<https://tetratherix.com/>

For personal use only